No Survival Benefit from Adding Cetuximab or Panitumumab to Oxaliplatin-Based Chemotherapy in the First-Line Treatment of Metastatic Colorectal Cancer in KRAS Wild Type Patients: A Meta-Analysis

Title
No Survival Benefit from Adding Cetuximab or Panitumumab to Oxaliplatin-Based Chemotherapy in the First-Line Treatment of Metastatic Colorectal Cancer in KRAS Wild Type Patients: A Meta-Analysis
Authors
Keywords
Chemotherapy, Meta-analysis, Toxicity, Cancer treatment, Colorectal cancer, Publication ethics, Cancer chemotherapy, Randomized controlled trials
Journal
PLoS One
Volume 7, Issue 11, Pages e50925
Publisher
Public Library of Science (PLoS)
Online
2012-12-01
DOI
10.1371/journal.pone.0050925

Ask authors/readers for more resources

Reprint

Contact the author

Add your recorded webinar

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now